Mesenchymal Stem Cell Transplantation in Newly Diagnosed Type-1 Diabetes Patients: A Phase I/II Randomized Placebo Controlled Clinical Trial

Izadi, Mahmoud; Nejad, Anavasadat Sadr Hashemi; Moazenchi, Maedeh; Masoumi, Safdar; Rabbani, Ali; Kompani, Farzad; Asl, Amir Abbas Hedayati; Abbasi, Fatemeh; Jarooghi, Neda; Meybodi, Mohamad Ali Mohseni; Setoodeh, Aria; Abbasi, Farzaneh; Hosseini, Seyedeh Esmat; Nia, Fatemeh Moeini; Yazdi, Reza Salman; Navabi, Roghayeh; Hajizadeh‐Saffar, Ensiyeh; Baharvand, Hossein

doi:10.21203/rs.3.rs-921850/v1

Cited by 2 publications

(2 citation statements)

References 67 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…232 The majority of trials have used adult mesenchymal stem cells derived from different origins, hematopoietic stem cells, or a combination of both. 227,233,234 Other trials have demonstrated the potential for the use of human embryonic stem cells and induced pluripotent stem cells to form functionally mature insulin-producing β cells. 227,235,236 The long-term safety of encapsulation devices and long-term viability of transplanted cells are persistent challenges to the widespread use of stem cell-based therapies.…”

Section: Prevention Of Hypoglycemiamentioning

confidence: 99%

“…It also overcomes the obstacle of limited donor availability 232 . The majority of trials have used adult mesenchymal stem cells derived from different origins, hematopoietic stem cells, or a combination of both 227,233,234 . Other trials have demonstrated the potential for the use of human embryonic stem cells and induced pluripotent stem cells to form functionally mature insulin‐producing β cells 227,235,236 .…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Pathophysiology and management of hypoglycemia in diabetes

Sanchez‐Rangel

Deajon‐Jackson

Hwang

2022

Annals of the New York Academy of Sciences

View full text Add to dashboard Cite

In the century since the discovery of insulin, diabetes has changed from an early death sentence to a manageable chronic disease. This change in longevity and duration of diabetes coupled with significant advances in therapeutic options for patients has fundamentally changed the landscape of diabetes management, particularly in patients with type 1 diabetes mellitus. However, hypoglycemia remains a major barrier to achieving optimal glycemic control. Current understanding of the mechanisms of hypoglycemia has expanded to include not only counter-regulatory hormonal responses but also direct changes in brain glucose, fuel sensing, and utilization, as well as changes in neural networks that modulate behavior, mood, and cognition. Different strategies to prevent and treat hypoglycemia have been developed, including educational strategies, new insulin formulations, delivery devices, novel technologies, and pharmacologic targets. This review article will discuss current literature contributing to our understanding of the myriad of factors that lead to the development of clinically meaningful hypoglycemia and review established and novel therapies for the prevention and treatment of hypoglycemia.

show abstract

Section: Prevention Of Hypoglycemiamentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Pathophysiology and management of hypoglycemia in diabetes

Sanchez‐Rangel

Deajon‐Jackson

Hwang

2022

Annals of the New York Academy of Sciences

View full text Add to dashboard Cite

show abstract

Emerging role and therapeutic application of mesenchymal stem cell (MSC) and MSC-derived exosome in Coronavirus disease-2019 (COVID-19) infection

Shi,

Yu,

et al. 2023

Recent Update on Mesenchymal Stem Cells

View full text Add to dashboard Cite

Over the past few years, the coronavirus disease-2019 (COVID-19) pandemic has infected billions of people worldwide. Most patients infected with COVID-19 present with fever, cough, headache, fatigue, and other clinical manifestations. For elderly patients or people with low immunity and underlying diseases, it is frequent to develop into severe or critical illness, which may even lead to multiple organ failure and death. Symptomatic treatment remains the most common treatment for patients with severe COVID-19 infection, whereas the effectiveness is limited. A large number of studies have shown that mesenchymal stem cells (MSCs) can inhibit viral growth, enhance tissue repair, and reduce inflammation, infection-induced cytokine storm, and multi-organ failure by secreting a variety of paracrine factors. In this paper, we summarized current relevant research, describe the mechanism of action and therapeutic effect of MSCs in patients with severe COVID-19 infection-related diseases, and discuss the therapeutic potential of MSCs and their exosome derivatives in patients with critical infections.

show abstract

Mesenchymal Stem Cell Transplantation in Newly Diagnosed Type-1 Diabetes Patients: A Phase I/II Randomized Placebo Controlled Clinical Trial

Cited by 2 publications

References 67 publications

Pathophysiology and management of hypoglycemia in diabetes

Pathophysiology and management of hypoglycemia in diabetes

Emerging role and therapeutic application of mesenchymal stem cell (MSC) and MSC-derived exosome in Coronavirus disease-2019 (COVID-19) infection

Contact Info

Product

Resources

About